CONTESSA 2 is a multinational, multicenter, Phase 2 study of tesetaxel, an investigational,
orally administered taxane, in patients with HER2 negative, HR Positive, LA/MBC not
previously treated with a taxane in the neoadjuvant, adjuvant or metastatic setting. This
Study complements CONTESSA, a multinational, multicenter, randomized, Phase 3 study in
patients with HER2 negative, HR positive LA/MBC previously treated with a taxane in the
neoadjuvant or adjuvant setting. 152 patients were enrolled, including 149 who received
treatment. Patients are administered tesetaxel at 27 mg/m2 orally once every 21 days on the
first day of each 21-day cycle plus capecitabine at 825 mg/m2 orally twice daily (for a total
daily dose of 1,650 mg/m2) for 14 days of each 21-day cycle. Patients in the dense
pharmacokinetics (PK) cohort receive a single dose of capecitabine monotherapy prior to
starting the combination regimen. Capecitabine is an oral chemotherapy agent that is
considered a standard-of-care treatment in LA/MBC. The primary efficacy endpoint is ORR as
assessed by the IRC. The secondary efficacy endpoints are duration of response (DoR) as
assessed by the IRC, progression-free survival (PFS) as assessed by the IRC, disease control
rate (DCR) as assessed by the IRC and overall survival (OS). CONTESSA 2 also investigates the
PK of tesetaxel.
Inclusion criteria:
1. Female or male patients at least 18 years of age
2. Histologically or cytologically confirmed breast cancer
3. HER2 negative disease based on local testing: American Society of Clinical
Oncology/College of American Pathologists (ASCO/CAP) guidelines should be utilized for
assessing HER2 status
4. HR (ER and/or PgR) positive disease based on local testing: ASCO/CAP guidelines should
be utilized for assessing HR status
5. Measurable disease per RECIST 1.1, including bone-only disease with measurable lytic
component.
Patients with bone-only metastatic cancer must have a measurable lytic or mixed
lytic-blastic lesion that can be accurately assessed by computed tomography (CT) or
magnetic resonance imaging (MRI). Patients with bone-only disease without a measurable
lytic component (ie, blastic-only metastasis) are not eligible.
Known metastases to the CNS are permitted but not required. The following criteria
apply:
- Patients must be neurologically stable and either off corticosteroids or
currently treated with a maximum daily dose of 4 mg of dexamethasone (or
equivalent), with no increase in corticosteroid dose within 7 days prior to
Enrollment (defined as the time of Sponsor approval of treatment dose)
- Patients with a history of CNS metastases but with no current evidence of CNS
lesions following local therapy are eligible
- Patients may have CNS metastases that are stable or progressing radiologically
- Patients with current evidence of leptomeningeal disease are not eligible
- Patients may have untreated brain metastases or previously treated brain
metastases, as long as no immediate local CNS-directed therapy is indicated
- Any prior whole brain radiation therapy must have been completed > 14 days prior
to the date of Enrollment
- Prior stereotactic brain radiosurgery is permitted
- CNS surgical resection must have been completed > 28 days prior to the date of
Enrollment; patient must have complete recovery from surgery
6. Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2
7. Prior endocrine therapy with or without a CDK 4/6 inhibitor unless endocrine therapy
is not indicated (ie, short relapse-free interval while on adjuvant endocrine therapy
[endocrine resistance]; rapidly progressing disease/visceral crisis; or endocrine
intolerance). Any targeted therapies approved for HER2 negative, HR positive LA/MBC,
including everolimus, are permitted as prior therapy. There is no limit to the number
of prior endocrine therapies.
8. Documented (including de novo): (a) locally advanced breast cancer that is not
considered curable by surgery and/or radiation; or (b) metastatic breast cancer
9. Adequate hematologic, hepatic and renal function, as evidenced by:
- Absolute neutrophil count (ANC) ≥ 1,500/μL without colony-stimulating factor
support
- Platelet count ≥ 100,000/μL
- Hemoglobin ≥ 10 g/dL without need for hematopoietic growth factor or transfusion
support
- Total bilirubin < 1.5 × upper limit of normal (ULN); does not apply to patients
with Gilbert's syndrome
- Alanine aminotransferase (ALT) < 3 × ULN unless hepatic metastases are present
then < 5 × ULN
- Aspartate aminotransferase (AST) < 3 × ULN unless hepatic metastases are present
then < 5 × ULN
- Alkaline phosphatase < 2.5 × ULN unless hepatic metastases are present then < 5 ×
ULN
- Calculated creatinine clearance ≥ 50 mL/min (by Cockcroft-Gault formula or local
standard)
- Serum albumin ≥ 3.0 g/dL
- Prothrombin time (PT) < 1.5 × ULN or international normalized ratio (INR) < 1.3
and partial thromboplastin time (PTT) < 1.5 × ULN, unless the patient is on a
therapeutic anticoagulant
10. Complete recovery to baseline or Grade 1 per National Cancer Institute (NCI) Common
Terminology Criteria for Adverse Events (CTCAE) version 5.0 from adverse effects of
prior surgery, radiotherapy, endocrine therapy, and other therapy, as applicable, with
the exception of Grade 2 alopecia from prior chemotherapy
11. Ability to swallow an oral solid-dosage form of medication
12. A negative serum pregnancy test within 7 days prior to the first dose of Study
treatment in women of childbearing potential (ie, all women except those who are post
menopause for ≥ 1 year or who have a history of hysterectomy or surgical
sterilization)
13. Women of childbearing potential must use an effective, non-hormonal form of
contraception from Screening throughout the Treatment Phase and until 70 days after
the last dose of Study treatment
- Acceptable methods include: copper intrauterine device or double barrier methods,
including male/female condoms with spermicide and use of contraceptive sponge,
cervical cap, or diaphragm
14. Male patients must use an effective, non-hormonal form of contraception from Screening
throughout the Treatment Phase and until 130 days after the last dose of Study
treatment
- Acceptable methods include: male/female condoms with spermicide, or vasectomy
with medical confirmation of surgical success
15. Written informed consent and authorization to use and disclose health information
16. Ability to comprehend and comply with the requirements of the Study
Exclusion criteria:
1. Two or more prior chemotherapy regimens for advanced disease
2. Prior treatment with a taxane at any dose
3. Prior treatment with capecitabine at any dose
4. Current evidence of leptomeningeal disease
5. Other cancer that required therapy within the preceding 5 years other than adequately
treated: (a) non-melanoma skin cancer or in situ cancer; or (b) following approval by
the Medical Monitor, other cancer that has a very low risk of interfering with the
safety or efficacy endpoints of the Study
6. Known human immunodeficiency virus infection, unless well controlled. Patients who are
on an adequate antiviral regimen with no evidence of active infection are considered
well controlled.
7. Active hepatitis B or active hepatitis C infection
8. Other severe acute or chronic medical or psychiatric condition or laboratory
abnormality that may increase the risk associated with Study participation or
investigational product administration or may interfere with the interpretation of
Study results and, in the judgment of the Investigator, would make the patient
inappropriate for entry into this Study.
9. Presence of neuropathy > Grade 1 per NCI CTCAE version 5.0
10. Anticancer treatment, including endocrine therapy, radiotherapy (except stereotactic
brain radiosurgery), chemotherapy, biologic therapy, or therapy in an investigational
clinical study, ≤ 14 days prior to the date of Enrollment
11. Major surgery ≤ 28 days prior to the date of Enrollment; patient must have complete
recovery from surgery
12. Less than 2 weeks or 5 plasma half-lives (whichever is greater) since last use of a
medication or ingestion of an agent, beverage, or food that is a known clinically
relevant strong inhibitor or known clinically relevant inducer of the cytochrome P450
(CYP)3A pathway (patients should discontinue taking any regularly-taken medication
that is a strong inhibitor or inducer of the CYP3A pathway)
13. History of hypersensitivity or unexpected reactions to capecitabine, fluoropyrimidine
agents or any of their ingredients
14. Known dihydropyrimidine dehydrogenase (DPD) deficiency. Testing for DPD deficiency
must be performed where required by local regulations, using a validated method that
is approved by local health authorities.
15. Pregnant or breastfeeding
16. If, in the opinion of the Investigator, the patient is deemed unwilling or unable to
comply with the requirements of the Study
17. Treatment with brivudine, sorivudine, or its chemically-related analogs ≤ 28 days
prior to the date of Enrollment
